259 related articles for article (PubMed ID: 32890789)
1. Effects of tamoxifen and aromatase inhibitors on the risk of acute coronary syndrome in elderly breast cancer patients: An analysis of nationwide data.
Choi SH; Kim KE; Park Y; Ju YW; Jung JG; Lee ES; Lee HB; Han W; Noh DY; Yoon HJ; Moon HG
Breast; 2020 Dec; 54():25-30. PubMed ID: 32890789
[TBL] [Abstract][Full Text] [Related]
2. Development of cardiometabolic risk factors following endocrine therapy in women with breast cancer.
Rillamas-Sun E; Kwan ML; Iribarren C; Cheng R; Neugebauer R; Rana JS; Nguyen-Huynh M; Shi Z; Laurent CA; Lee VS; Roh JM; Huang Y; Shen H; Hershman DL; Kushi LH; Greenlee H
Breast Cancer Res Treat; 2023 Aug; 201(1):117-126. PubMed ID: 37326764
[TBL] [Abstract][Full Text] [Related]
3. Aromatase inhibitors use and risk for cardiovascular disease in breast cancer patients: A population-based cohort study.
Sund M; Garcia-Argibay M; Garmo H; Ahlgren J; Wennstig AK; Fredriksson I; Lindman H; Valachis A
Breast; 2021 Oct; 59():157-164. PubMed ID: 34265496
[TBL] [Abstract][Full Text] [Related]
4. Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials.
Khosrow-Khavar F; Filion KB; Al-Qurashi S; Torabi N; Bouganim N; Suissa S; Azoulay L
Ann Oncol; 2017 Mar; 28(3):487-496. PubMed ID: 27998966
[TBL] [Abstract][Full Text] [Related]
5. Event-free survival following early endometrial events in breast cancer patients treated with anti-hormonal therapy: A nationwide claims data study.
Lee Y; Park YR; Kim HR; Lee JW
Medicine (Baltimore); 2019 Jan; 98(2):e13976. PubMed ID: 30633178
[TBL] [Abstract][Full Text] [Related]
6. Aromatase inhibitors and the incidence of Parkinson disease: A population-based cohort study.
Khosrow-Khavar F; Azoulay L; Montastruc JL; Montastruc F; Renoux C
Cancer; 2022 Jun; 128(12):2339-2347. PubMed ID: 35363379
[TBL] [Abstract][Full Text] [Related]
7. Association of aromatase inhibitors with coronary heart disease in women with early breast cancer.
Seruga B; Zadnik V; Kuhar CG; Marinko T; Cufer T; Zakotnik B; Zorman D; Ocana A; Amir E
Cancer Invest; 2014 May; 32(4):99-104. PubMed ID: 24548302
[TBL] [Abstract][Full Text] [Related]
8. Incident comorbidities after tamoxifen or aromatase inhibitor therapy in a racially and ethnically diverse cohort of women with breast cancer.
Gupta T; Purington N; Liu M; Han S; Sledge G; Schapira L; Kurian AW
Breast Cancer Res Treat; 2022 Nov; 196(1):175-183. PubMed ID: 36030472
[TBL] [Abstract][Full Text] [Related]
9. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer.
Perez EA
Ann Oncol; 2007 Sep; 18 Suppl 8():viii26-35. PubMed ID: 17890211
[TBL] [Abstract][Full Text] [Related]
10. Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study.
Khosrow-Khavar F; Filion KB; Bouganim N; Suissa S; Azoulay L
Circulation; 2020 Feb; 141(7):549-559. PubMed ID: 32065766
[TBL] [Abstract][Full Text] [Related]
11. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
Gradishar WJ
Oncology; 2005; 69(1):1-9. PubMed ID: 16088229
[TBL] [Abstract][Full Text] [Related]
12. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
Gibson LJ; Dawson C; Lawrence DH; Bliss JM
Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
[TBL] [Abstract][Full Text] [Related]
13. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.
Amir E; Seruga B; Niraula S; Carlsson L; Ocaña A
J Natl Cancer Inst; 2011 Sep; 103(17):1299-309. PubMed ID: 21743022
[TBL] [Abstract][Full Text] [Related]
14. Aromatase inhibitors and the risk of colorectal cancer in postmenopausal women with breast cancer.
Khosrow-Khavar F; Yin H; Barkun A; Bouganim N; Azoulay L
Ann Oncol; 2018 Mar; 29(3):744-748. PubMed ID: 29293897
[TBL] [Abstract][Full Text] [Related]
15. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
Mouridsen HT
Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
[TBL] [Abstract][Full Text] [Related]
16. Cardiotoxicity of Use of Sequential Aromatase Inhibitors in Women With Breast Cancer.
Khosrow-Khavar F; Bouganim N; Filion KB; Suissa S; Azoulay L
Am J Epidemiol; 2020 Oct; 189(10):1086-1095. PubMed ID: 32338279
[TBL] [Abstract][Full Text] [Related]
17. Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare population-based study.
Kamaraju S; Shi Y; Smith E; Nattinger AB; Laud P; Neuner J
Clin Cardiol; 2019 Jan; 42(1):93-100. PubMed ID: 30443921
[TBL] [Abstract][Full Text] [Related]
18. Hormonal therapy for breast cancer and diabetes incidence among postmenopausal women.
Santorelli ML; Hirshfield KM; Steinberg MB; Rhoads GG; Lin Y; Demissie K
Ann Epidemiol; 2016 Jun; 26(6):436-40. PubMed ID: 27157863
[TBL] [Abstract][Full Text] [Related]
19. Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study.
Hong N; Yoon HG; Seo DH; Park S; Kim SI; Sohn JH; Rhee Y
Eur J Cancer; 2017 Sep; 82():103-114. PubMed ID: 28651157
[TBL] [Abstract][Full Text] [Related]
20. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
